Intermediate compound used for preparing Ambrisentan, preparation method thereof, and preparation of Ambrisentan

A compound and an independent technology, applied in the field of preparation of ambrisentan and intermediate compounds of ambrisentan, can solve the problems of low resolution yield, increased cost, low atom utilization rate and the like, and achieve high yield, The effect of simple operation, improved atom utilization and synthesis efficiency

Inactive Publication Date: 2013-12-04
SHANGHAI INST OF PHARMA IND
View PDF7 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0020] At present, the existing literature reports adopt the method of splitting to prepare ambrisentan (S-I), the splitting yield is not high, the utilization rate of atoms is low, and the cost is increased.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Intermediate compound used for preparing Ambrisentan, preparation method thereof, and preparation of Ambrisentan
  • Intermediate compound used for preparing Ambrisentan, preparation method thereof, and preparation of Ambrisentan
  • Intermediate compound used for preparing Ambrisentan, preparation method thereof, and preparation of Ambrisentan

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach

[0079] The present invention provides an intermediate compound IV for the preparation of ambrisentan and its enantiomers, the structural formula of which is as follows:

[0080]

[0081] Ambrisentan is prepared by adopting the intermediate without splitting, and the atom economy is high.

[0082] The present invention further provides a method for preparing the compound shown in formula IV, the method comprising removing the protecting group from the compound shown in formula III in the presence of a reaction solvent to obtain the compound shown in formula IV,

[0083]

[0084] Among them, R 1 , R 2 each independently selected from a hydrogen atom, C 1 -C 6 Alkyl, C 1 -C 6 Haloalkyl, phenyl or C 1 -C 6 Alkoxy, halogen, hydroxy-substituted phenyl, or R 1 and R 2 Together with the carbon atom they are attached to form C 3 -C 6 Cycloalkyl, more preferably, R 1 and R 2each independently selected from a hydrogen atom, methyl, ethyl, propyl, tert-butyl, trichlorom...

Embodiment 1a

[0128] Weigh 80g (0.44mol) of mannitol and 480g (3.5mol) of zinc chloride, dissolve in 1000ml of acetone, and stir at 20°C for 14h. TLC (PE: EA = 1: 2) monitored that the reaction was complete. Weigh 500g of potassium carbonate and dissolve it in 1000ml of water, add the aqueous solution of potassium carbonate and 1.5L of dichloromethane into the system and stir for 30min, filter and wash the filter residue with 100mL of dichloromethane, extract the aqueous phase with 500ml of dichloromethane, and combine the organic phases , the organic phase was washed once with saturated brine 300mL, anhydrous Na 2 SO 4 dry. After filtration, the filtrate was spin-dried to obtain 125.2 g of a pale yellow solid (Compound X-a). Add 150ml of isopropyl ether and 100ml of petroleum ether, heat at 80°C, and cool to room temperature to obtain 49g of white solid. Yield 43%. Its structural identification data are as follows:

[0129] MS: [M+H] + : 263.18[M+Na] + : 303.22.

Embodiment 2a

[0131] Weigh 48.3g (0.18mol) of (Compound X-a) and dissolve it in 480mL of dichloromethane. Add water 33ml and NaIO in turn 4 49.5g (0.23mol), stirred and reacted at 20°C for 5h. TLC (PE: EA = 1: 1) monitored that the reaction was complete. After filtration and rotary evaporation at 40°C, add (methanol:water=9:1) mixed solution 500ml and sodium bicarbonate 70g (0.83mol), add bromine 18.8ml (0.36mol) dropwise in ice-water bath, and stir at 20°C Overnight, TLC (PE: EA = 4: 1) detection, phosphomolybdic acid color development, add saturated sodium thiosulfate 15ml in ice water bath, the system completely faded, add 700ml of dichloromethane, 300ml of water to separate, the organic phase with saturated Wash once with 300 mL of saline, anhydrous Na 2 SO 4 dry. After filtering, the filtrate was spin-dried to obtain 44.3 g of a colorless liquid (Compound XI-a).

[0132] MS:[M+H] + :161.08;

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an intermediate IV used for preparing Ambrisentan, a preparation method thereof, and a preparation method of Ambrisentan. The intermediate compound is a compound in a S-shape, is capable of directly synthesizing Ambrisentan without separation, thus the defects in the prior art are overcome, the atom utilization rate of synthesis is improved, the cost is reduced, and the intermediate is suitable for being applied to industrial production. The invention also discloses other intermediates VI, VII, and VIII, which are used for preparing Ambrisentan, and two preparation methods of Ambrisentan.

Description

technical field [0001] The invention relates to the field of medicinal chemistry, in particular to intermediate compounds for preparing ambrisentan, a preparation method of these intermediates and a method for preparing ambrisentan. Background technique [0002] Pulmonary arterial hypertension (PAH) is a group of diseases pathologically characterized by abnormally elevated pulmonary artery pressure and progressive occlusion of the pulmonary vascular bed, eventually leading to progressive increase in vascular resistance and right heart failure. At present, pulmonary arterial hypertension drugs are mainly divided into phosphodiesterase-5 (PDE-5) inhibitors, prostacyclins and endothelin receptor antagonists according to their different mechanisms of action. Among them, endothelin receptor antagonists can completely bind to endothelin receptors, thereby achieving the purpose of delaying disease progression. Therefore, in recent years, the research on pulmonary arterial hypertens...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07C43/178C07C41/28C07C69/007C07C67/14C07D317/22C07D317/72C07D239/34
CPCC07D239/32C07D239/34C07D317/10C07C43/1782C07C41/28C07D317/22A61P9/12
Inventor 林峰朱晓峰陈建丽徐秋龙
Owner SHANGHAI INST OF PHARMA IND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap